These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24586944)

  • 1. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
    Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
    Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
    Morelli E; Biamonte L; Federico C; Amodio N; Di Martino MT; Gallo Cantafio ME; Manzoni M; Scionti F; Samur MK; Gullà A; Stamato MA; Pitari MR; Caracciolo D; Sesti S; Frandsen NM; Rossi M; Neri A; Fulciniti M; Munshi NC; Tagliaferri P; Tassone P
    Blood; 2018 Sep; 132(10):1050-1063. PubMed ID: 29997223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
    Di Martino MT; Gullà A; Cantafio ME; Lionetti M; Leone E; Amodio N; Guzzi PH; Foresta U; Conforti F; Cannataro M; Neri A; Giordano A; Tagliaferri P; Tassone P
    Oncotarget; 2013 Feb; 4(2):242-55. PubMed ID: 23479461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
    Monoe Y; Jingushi K; Kawase A; Hirono T; Hirose R; Nakatsuji Y; Kitae K; Ueda Y; Hase H; Abe Y; Adachi J; Tomonaga T; Tsujikawa K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.
    Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.
    Gu C; Jing X; Holman C; Sompallae R; Zhan F; Tricot G; Yang Y; Janz S
    BMC Cancer; 2018 Nov; 18(1):1152. PubMed ID: 30463534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression.
    Murphy BL; Obad S; Bihannic L; Ayrault O; Zindy F; Kauppinen S; Roussel MF
    Cancer Res; 2013 Dec; 73(23):7068-78. PubMed ID: 24145352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth.
    Yan LX; Wu QN; Zhang Y; Li YY; Liao DZ; Hou JH; Fu J; Zeng MS; Yun JP; Wu QL; Zeng YX; Shao JY
    Breast Cancer Res; 2011 Jan; 13(1):R2. PubMed ID: 21219636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
    Di Martino MT; Campani V; Misso G; Gallo Cantafio ME; Gullà A; Foresta U; Guzzi PH; Castellano M; Grimaldi A; Gigantino V; Franco R; Lusa S; Cannataro M; Tagliaferri P; De Rosa G; Tassone P; Caraglia M
    PLoS One; 2014; 9(2):e90005. PubMed ID: 24587182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
    Cosco D; Cilurzo F; Maiuolo J; Federico C; Di Martino MT; Cristiano MC; Tassone P; Fresta M; Paolino D
    Sci Rep; 2015 Dec; 5():17579. PubMed ID: 26620594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LNA Inhibitor in microRNA miR-23b as a Potential Anti-proliferative Option in Human Hepatocellular Carcinoma.
    Najafi Z; Sharifi M; Javadi G
    J Gastrointest Cancer; 2020 Mar; 51(1):109-115. PubMed ID: 30815771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma.
    Li Z; Liu L; Du C; Yu Z; Yang Y; Xu J; Wei X; Zhan F; Lai Y; Qiu L; Hao M
    Cancer Gene Ther; 2020 Dec; 27(12):869-877. PubMed ID: 31988477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.